The year's most popular stories

Share this article:
The year's most popular stories
The year's most popular stories

There are lots of ways to write the kind of story that ends up on a list like this. You could take a deep dive sharing exclusive projections for industry marketing spend. You can seriously examine the aggressive pricing for oncology drugs in the US. Or you can pen a commentary about Angelina Jolie's views on holistic treatment.

MM&M's year-end list also captures approval and pipeline analysis (Eliquis, Sovaldi, Lemtrada), insights into what doctors need—as opposed to what pharma thinks they want—and a look at medical advertising's best DTC ads ever. Here are the 10 that sparked heaviest reader interest in 2013:

1. Angelina Jolie's flawed message

2. Healthcare Marketers Trend Report: The Big Shift

3. Will Kadcyla suffer the same fate as Zaltrap?

4. Year-end approval clears Eliquis for launch

5. Docs to pharma marketers: you're not getting it

6. Merck buys controlling stake in Physicians Interactive

7. Lemtrada's future in doubt after reviewers flag safety issues

8. MM&M's Best DTC Ads Ever

9. Is the current agency model a joke?

10. The Pipeline Report 2014: Class Seekers

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.